Nexturn Bioscience (CEO Joo Han Lee) announced on April 29 that it plans to improve its business structure by pursuing a small-scale merger by absorption without capital increase with its subsidiary Nexturn Bio, aiming to maximize synergy effects through cost reduction and enhanced management efficiency.
The merger will be a small-scale absorption-type merger without issuing new shares. Nexturn Bioscience will be the surviving company, while Nexturn Bio will be dissolved. The record date for determining shareholders is May 15, and Nexturn Bio is scheduled to be dissolved as of July 1.
A company representative stated, "Nexturn Bio is a wholly owned subsidiary of Nexturn Bioscience, established in April 2021. Since its founding, it has made strategic investments to strengthen competitiveness in next-generation bio·healthcare, IT, and digital transformation sectors. The merger is being carried out to achieve cost reduction and more efficient management and administration."
The representative added, "Through this merger, we plan to further enhance corporate competitiveness by achieving efficient management and administration of our existing subsidiaries, including Cha Healthcare, Rosvivo, and Clush, in which we have invested."
Meanwhile, in July 2023, Nexturn Bio made a strategic investment of 12 billion KRW in Cha Healthcare through the 'Daishin-Y2HC New Technology Investment Association No. 1.' Cha Healthcare operates a medical network spanning seven countries, including the United States, Australia, Singapore, and Japan. The company aims to strengthen its position in the global market and is preparing for an initial public offering (IPO) in 2026.
Nexturn Bio also invested in Rosvivo to focus on a new drug development project based on miRNA technology, which is effective in treating diabetes and obesity. If the new drug derived from this project is successfully commercialized, it is expected to significantly strengthen competitiveness across the healthcare industry and provide a strong growth engine for overseas expansion.
In May last year, Nexturn Bio invested in Clush, a company specializing in cloud-native technology, through Aon Investment. Clush attracted investment from Naver Cloud in October last year and received additional investment from P&I Investment in November. Recently, Clush supplied and built PaaS platforms for major domestic financial holding companies and has also been selected as a solution for efficient management of AI infrastructure in the GenAI business, thereby contributing to enhancing AI service competitiveness in the financial sector.
Additionally, the company has major subsidiaries, including EV Advanced Materials, a KOSDAQ-listed company; Mirae Industries, a KOSPI-listed company; and Roll Korea, an unlisted company.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
